Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Boehringer Duloxetine Co-Promotion Lets Lilly Focus On Cialis Launch

Executive Summary

Lilly and Boehringer Ingelheim's co-promotion agreement for duloxetine in stress urinary incontinence allows Lilly to focus on Cialis while retaining a stake in its duloxetine urology franchise

You may also be interested in...



Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA

Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy

Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA

Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy

Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?

Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq

Related Content

UsernamePublicRestriction

Register

PS040908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel